Company Overview

Aethlon Medical, Inc. is a U.S.-based biotechnology and medical device company focused on developing therapeutic technologies designed to treat cancer and life-threatening infectious diseases. The company operates primarily within the biopharmaceutical, oncology, and extracorporeal blood filtration industries. Its core technology platform is the Hemopurifier®, an investigational blood filtration device intended to remove disease-promoting extracellular vesicles and certain viruses from the bloodstream. Aethlon Medical’s activities are centered on clinical-stage development, regulatory advancement, and strategic research collaborations rather than large-scale commercial product sales.

The company’s primary revenue sources historically have consisted of government contracts, research grants, collaborative agreements, and limited device-related development funding rather than recurring commercial healthcare revenue. Aethlon Medical has positioned itself within the emerging field of therapeutic apheresis and extracorporeal immunotherapy, with a strategic emphasis on oncology applications and viral pathogen removal technologies. Founded in 1984 and headquartered in San Diego, California, the company evolved from early infectious disease filtration research into a broader precision blood purification platform targeting oncology and critical care applications.

Business Operations

Aethlon Medical operates largely through a single reporting structure focused on therapeutic blood filtration technologies, with the Hemopurifier® serving as its principal asset and development platform. The device is designed for use alongside existing medical therapies and is being evaluated for applications involving solid tumors and infectious diseases. The company’s operational activities include clinical trials, regulatory submissions, device engineering, manufacturing coordination, and academic or institutional collaborations. Aethlon has historically pursued investigational studies involving viral pathogens such as hepatitis C and COVID-19, while more recent strategic emphasis has shifted toward oncology indications involving extracellular vesicle removal.

Operations are primarily based in the United States, though the company has engaged with international clinical and research institutions over time. Aethlon Medical relies on third-party manufacturing, clinical research organizations, and specialized medical development partners rather than vertically integrated production infrastructure. The company’s intellectual property portfolio includes patents and proprietary know-how related to affinity-based blood filtration technologies. Public filings and company disclosures identify collaborations with government agencies and research institutions, though the company does not currently maintain large-scale commercial subsidiaries or broad multinational operating divisions comparable to larger medical technology firms.

Strategic Position & Investments

Aethlon Medical’s strategic direction centers on advancing the Hemopurifier® through clinical validation and regulatory development in oncology and infectious disease settings. A key growth initiative involves evaluating the device as a complementary therapy for patients with advanced or metastatic cancers, particularly where extracellular vesicles may contribute to immune suppression or treatment resistance. The company has also explored biodefense and pandemic-response applications through prior collaborations and government-supported initiatives. Its strategy emphasizes niche therapeutic applications where blood purification technologies may provide adjunctive benefit alongside conventional treatments.

The company has historically invested in clinical trials, regulatory engagement with the U.S. Food and Drug Administration, and expansion of its intellectual property portfolio. Aethlon Medical has not been associated with large-scale acquisitions compared with larger biotechnology peers, and publicly available information does not indicate a diversified portfolio of operating subsidiaries. Its positioning within the extracorporeal therapy market is differentiated by its focus on selective affinity filtration targeting circulating extracellular vesicles and viral particles. Data regarding long-term commercialization timelines and market adoption remains inconclusive based on available public sources.

Geographic Footprint

Aethlon Medical is headquartered in San Diego, California, and its operational footprint is concentrated primarily within the United States. The company conducts regulatory, administrative, and development activities domestically while participating in selected international clinical and research collaborations. Its technology development and investor activities are principally tied to the U.S. biotechnology and medical device sectors.

Although Aethlon Medical does not maintain a broad multinational commercial infrastructure, its investigational technology has attracted attention from institutions and researchers in regions including North America, Europe, and parts of Asia through scientific conferences, collaborative studies, and clinical discussions. The company’s international exposure is therefore driven more by research engagement and intellectual property reach than by direct operational scale or global manufacturing presence.

Leadership & Governance

Aethlon Medical is led by executives with backgrounds in biotechnology, medical devices, finance, and healthcare operations. The company’s governance structure follows public-company reporting standards and oversight requirements applicable to Nasdaq-listed issuers. Strategic leadership has focused on advancing clinical-stage therapeutic technologies, maintaining regulatory compliance, and securing financing necessary to support ongoing development programs.

Key executives and leadership include:

• James B. Frakes – Chief Executive Officer and Chief Financial Officer
• Steven LaRosa, M.D. – Chief Medical Officer
• Mark R. Pykett, M.D., Ph.D. – Chairman of the Board
• Thomas “Tom” Malone – Director
• Angela M. Katsanis – Director

Company leadership has consistently emphasized clinical validation, regulatory advancement, and strategic partnerships as central elements of Aethlon Medical’s long-term development strategy. Information regarding broader executive succession planning or expanded international management infrastructure remains limited in publicly available disclosures.